Skip to content

Effects of robotic and laparoscopic-assisted surgery on the clinical outcomes of locally advanced gastric cancer: a randomized controlled study

Effects of robotic and laparoscopic-assisted surgery on the clinical outcomes of locally advanced gastric cancer: a randomized controlled study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000039195
Enrollment
Unknown
Registered
2020-10-21
Start date
2020-10-30
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

A:robotic assisted surgery

Sponsors

Affiliated Hospital of Qingdao University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Preoperative endoscopy and biopsy confirmed gastric adenocarcinoma; 2. Primary tumor resectable; 3. With gastric cancer that can be treated with radical resection: cTNM II-III A defined in 7th edition UICC / AJCC; 4. Age between 18 and 75 Years old, male or female, life expectancy >=12 weeks, BMI <= 30 kg/m2 (medium or slim body), without other severe diseases; 5. WHO performance status < 2; 6. Informed consent obtained from patients or their appointed agent.

Exclusion criteria

Exclusion criteria: 1. Patients with other gastric malignant diseases, such as lymphoma and stromal tumors, etc.; 2. Patients suffering from malignant diseases before the study; 3. With other severe comorbidities and cannot tolerate laopen surgery can not tolerate laparoscopic surgery or open surgery: such as severe heart and lung diseases, heart function below clinical stage 2, pulmonary infection, moderate to severe COPD, chronic bronchitis, severe diabetes and / or renal insufficiency, severe hepatitis and / or function below the rank of CHILD B grade, and severe malnutrition, etc; 4. Patients with previous history of upper abdominal surgery; 5. Patient undergo emergency surgery due to bleeding or perforation of gastric cancer; 6. Patients treated with neoadjuvant chemotherapy or radiation therapy which might affect the efficacy observation.

Design outcomes

Primary

MeasureTime frame
3-year survival rate;5-year survival rate;Postoperative pain;Quality of Life;Compliance rate of lymph node dissection;Operative mortality;Negative rate of tumor margins;Complications;Operation time;The number of lymph node dissection;Postoperative stress;time to postoperative first flatus;Immune response;Blood loss;postoperative first flatus;

Countries

China

Contacts

Public ContactZhou Yanbing

Affiliated Hospital of Qingdao University

zhouyanbing999@aliyun.com+86 13708971773

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026